Recurrent genital herpes: features of diagnosis and potential of modern therapy
https://doi.org/10.21518/2079-701X-2018-7-74-78
Abstract
Genital herpes (GH) is top-ranked in the sexually transmitted infection (STIs) rating, which is associated with a lifelong persistence of the virus in the infected patients, polymorphism of clinical manifestations of herpes infection, high percentage of relapsing forms of disease progression. Combination therapy with local use of activated glycyrrhizic acid-containing drug contributes to reducing the duration of GH relapse, more rapid healing of skin and mucosal lesions, increasing duration of the remission period. A patient can plan pregnancy in the absence of GH recurrence during pregravid preparation, in normotsenoze vagina and the absence of type 1 herpes simplex virus (HSV) DNA and type 2 HSV in the genital tract according to PCR test results, sufficient type-specific antiherpetic antibodies titer and absence of GH relapse in sexual partner.
About the Authors
N. M. Nazarova
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia, Moscow
Russian Federation
MD
Russian Federation
MD
S. V. Pavlovich
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia, Moscow
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
M. E. Nekrasova
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. WHO document. The Global Strategy for the Prevention and Control of Sexually Transmitted Infections for 2006-2015 M., 2007.
2. WHO. News bulletin. 2013, 110.
3. Resources and activities of medical dermatovenereological organizations. Incidence of sexually transmitted infections, infectious skin diseases and skin diseases (Statistical Materials). M., 2016, p. 99, www.mednet.ru.
4. Modi S, Van L, Gewirtzman A et al. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Ris Man, 2008, 4(2): 409–417.
5. Marchenko LA, Lushkova IP, Shurshalina AV. Treatment of patients with recurrent genital herpes. Vopr. Gin. Akush. i Perinatologii, 2004, 6: 90-93
6. Bartlett BL, Tyring SK, Fife K et al. Famciclovir treatment options for pa- tients with frequent outbreaks of recurrent genital herpes: The RELIEF trial. J ClinVirol, 2008, 43: 190–195.
7. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infec- tions: an evidence-based review. Arch Int Med, 2008, 168(11): 1137–1144.
8. CDC. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep, 2015, 64(3): 27–32.
9. Federal clinical guidelines. Dermatovenereology 2015: Skin diseases. Sexually Transmitted Infections. 5th ed., reviewed and added. M.: Business Express, 2016: 655-664.
10. Patel R, Alderson S, Geretti A, et al. European guidelines for the management of patients with genital herpes (2010). Effektivnaya Farmakoterapiya (Akusherstvo i Ginekologiya, 2012, 2: 4-15.
11. Management of patients with sexually transmitted infections and urogenital infections. Clinical guidelines. M., 2012: 20-24.
12. Shurshalina AV, Krechetova LV, Ziganshina MM, Sukhikh GT. Akusherstvo i Ginekologiya, 2009, 3: 1-4.
13. Kuzmin VN. Modern view of the clinical course, diagnosis and therapy of genital herpes in women. Lechashchy Vrach, 2009, 3: 42-47.
14. Abakarova PR, Mezhevitinova EA, Mheryan AN, Dovletkhanova ER. Activated glycyrrhizic acid in the combination therapy of recurrent genital herpes. Meditsinsky Sovet, 2017, 13: 128-132.
15. Sexually Transmitted Diseases Treatment Guidelines. Cent Dis Control Prev, 2010: 20–25.
Review
For citations:
Nazarova NM, Pavlovich SV, Nekrasova ME. Recurrent genital herpes: features of diagnosis and potential of modern therapy. Meditsinskiy sovet = Medical Council. 2018;(7):74-78. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-74-78
Views:
713
Email this article 